Prokineticin 2 (PROK2) is an important factor for angiogenesis in colorectal cancer
Authors:
Open Access
- 30 June 2015
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (28) , 26242-26251
Abstract
Prokineticin 2 (PROK2) is an important factor for angiogenesis in colorectal cancerKeywords
This publication has 36 references indexed in Scilit:
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- Kallmann syndromeEuropean Journal of Human Genetics, 2008
- Disruption of the Circadian Output Molecule Prokineticin 2 Results in Anxiolytic and Antidepressant-like Effects in MiceNeuropsychopharmacology, 2008
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III StudyJournal of Clinical Oncology, 2008
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Microenvironmental regulation of metastasisNature Reviews Cancer, 2008
- Loss-of-function mutation in the prokineticin 2 gene causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadismProceedings of the National Academy of Sciences, 2007
- Fibroblasts in cancerNature Reviews Cancer, 2006
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971